SHIFTING FROM ORAL CONTRACEPTIVES TO NORETHISTERONE ACETATE, OR VICEVERSA, BECAUSE OF DRUG INTOLERANCE: DOES THE CHANGE BENEFIT WOMEN WITH ENDOMETRIOSIS?

Paolo Vercellini, M.D.[a,b]	ORCID 0000-0003-4195-0996	paolo.vercellini@unimi.it
Federica Ottolini, M.D.[a]		federica_ottolini@libero.it
Maria Pina Frattaruolo, M.D.[a,b]	ORCID 0000-0001-7288-0113	mp.frattaruolo@gmail.com
Laura Buggio, M.D.[a,b]	ORCID 0000-0002-1199-1888	buggiolaura@gmail.com
Anna Roberto, Biol.Sci.D.[c]	ORCID 0000-0002-6756-1297	anna.roberto@marionegri.it
Edgardo Somigliana, M.D.[a,b]	ORCID 0000-0002-0223-0032	dadosomigliana@yahoo.it

From the [a] Department of Clinical Sciences and Community Health, Università degli Studi di Milano and [b]Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Via Commenda, 12 - 20122 Milan, Italy; [c]Department of Public Health, IRCCS Mario Negri Institute for Pharmacological Research, Via La Masa 19, 20156 Milan, Italy.

Correspondence:

Prof. Paolo Vercellini

Istituto Ostetrico e Ginecologico "Luigi Mangiagalli", Via Commenda 12 – 20122 Milano, Italy

Tel. +3902.55032917; fax: +3902.55032818; electronic address: paolo.vercellini@unimi.it

SHORT TITLE: Intolerance to estrogen-progestins and progestins for endometriosis

KEY WORDS: endometriosis; medical treatment; estrogen-progestin combinations; progestins; norethisterone acetate; pelvic pain.

ABSTRACT

Background/Aims: Oral contraceptives (OC) and norethisterone acetate (NETA) are among first-line medical therapies for symptomatic endometriosis, but their use is sometimes associated with intolerable side effects. We investigated whether shifting from low-dose OC to NETA (2.5 mg/day), or viceversa, improved tolerability.

Methods

Sixty-seven women willing to discontinue their treatment because of intolerable side effects despite good pain relief, were enrolled in a self-controlled study, and shifted from OC to NETA (n = 35) or from NETA to OC (n = 32). The main study outcome was satisfaction with treatment 12 months after the change. Tolerability, pain symptoms, health-related quality of life, psychological status, and sexual functioning were also evaluated.

Results

After treatment change, good tolerability was reported by 37% of participants who shifted to NETA, and by 52% of those who shifted to OC. At 12-month assessment, 51% of women intolerant to OC were satisfied with NETA, and 65% of those intolerant to NETA were satisfied with OC (intention-to-treat analysis). Other study variables did not vary substantially.

Conclusions

In selected endometriosis patients, shifting from OC to NETA, or viceversa, because of side effects, improved tolerability. Better results were observed when substituting NETA with OC rather than the other way round.

INTRODUCTION

Combined oral contraceptives (OC) and progestins are indicated by major international guidelines as the first-line medical treatment options for women not seeking conception and with endometriosis-associated pelvic pain [1-4]. Overall, about two thirds of patients appear to benefit from these therapies [5-16]. The main reason of treatment failure in the remaining third, in addition to inefficacy, is drug intolerance. As untoward effects of OCs and progestins partly differ, a shift from the former to the latter compounds, or viceversa, could allow continuing treatment with a safe, effective, and unexpensive medication without the need for stepping up to a drug with a less favorable therapeutic profile or resorting to surgery. However, very limited information is available on what should a patient expect from these changes [17, 18]. The answers to these questions seem important as the clinical issue is not rare and may interfere with health-related quality of life and disease management. Given this background, we sought to investigate whether shifting from an OC to a progestin, or viceversa, specifically because of drug intolerance, is of benefit in terms of relief from side effects and, in case these measures are effective, whether they imply reduced efficacy on pain symptoms.

MATERIALS AND METHODS

The main objective of the present study was to assess the proportion of patients satisfied with their therapy 12 months after a change from a low-dose, monophasic OC to norethisterone acetate (NETA), or viceversa, because of side effects intolerable to the point of requesting treatment discontinuation. Therefore, in the present study population, patient dissatisfaction was not caused by inefficacy on pain symptoms. Secondary objective was the evaluation of variations in pain symptoms, health-related quality of life, psychological status, and sexual function associated with the shift from OC to NETA, or viceversa.

A prospective, self-controlled study design was adopted because it allows within-person comparisons avoiding the potential confounding caused by differences between patients [19]. The investigation was performed in an academic department specializing in the management of

endometriosis, and the competent Institutional Review Board approved the study. Patients signed an informed consent form before enrollment. Women who denied their consensus were excluded.

Patients

We considered 18- to 40-year old women, not seeking conception, with a surgical diagnosis of endometriosis in the previous 24 months or with a current non-surgical diagnosis of endometriosis, and using an OC or NETA for pelvic pain, but unwilling to continue the current treatment because of dissatisfaction due to intolerable side effects. Non-surgical diagnoses were based on previously published criteria [20-22]. Participants were recruited during the period August 2014 - July 2015.

Women were informed that: i) OC or NETA may, in some women, cause side effects, frequently because of the estrogen component in the former case, and of residual androgenic activity in the latter case; ii) switching to, respectively, a progestin monotherapy or an OC containing another type of progestin could result in subjective improvement; iii) also the alternative drug was associated with side effects, and the efficacy of the proposed change of therapy was uncertain; iv) OCs and progestins are indicated by major international guidelines as the first-line treatment for endometriosis-associated pelvic pain [1-4], but that other medical therapies exist, although characterized by a less favorable balance between benefits, harms and costs [23-27]; v) laparoscopic surgery was a reasonable alternative in case they declined a change in pharmacological treatment, but that pain and lesion recurrence was about 10% a year without long-term postoperative medical therapy [28, 29].

Treatments

a. Switch from OC to NETA

Norethisterone acetate, a 19-nortestosterone derivative progestin, has been repeatedly evaluated in women with endometriosis [6, 9-11, 30-32], and has been routinely used in our referral center for several years [7, 14-16]. Norethisterone acetate is approved by the FDA and the Italian Ministry of Health for the treatment of endometriosis and is reimbursed by the Italian National Health System.

Norethisterone acetate was prescribed at the dose of 2.5 mg once a day, *per os*. The progestin was started after 4-7 days since OC discontinuation, depending on the type of OC previously used.

b. Switch from NETA to OC

The OCs used in our center were monophasic formulations containing ethinyl-estradiol 0.015 mg and gestodene 60 mg or, in case of spotting, ethinyl-estradiol 0.02 mg and desogestrel 150 mg. In smokers and in those with a BMI $\geq$ 30, a combination of ethinyl-estradiol 0.02 mg and levonorgestrel 100 mg was prescribed. Women were allowed to choose between cyclic and continuous OC use based on their preference because the reason for the change of medication was intolerance, not inefficacy on pain. A pause without treatment was not suggested before starting OC.

NETA and OC were continued without preplanned time limits. However, for the purpose of the present study, only the first 12 months of use have been evaluated. In case of prolonged spotting ($\geq$ 7 days) or breakthrough bleeding during NETA or continuous OC use, the patients were advised to discontinue treatment for one week in the former case, and 4-7 days in the latter case.

Measurements

All patients assisted in our center systematically undergo clinical and ultrasonographic evaluation every six months. On these occasions, women are routinely asked to complete five questionnaires, two on pain (a numeric rating scale, NRS; and a multi-dimensional categorical rating scale, MCRS), one on quality of life (the Short Form-12 questionnaire, SF-12), one on psychological status (the Hospital Anxiety and Depression scale, HADS), and one on sexual functioning (the Female Sexual Function Index, FSFI). Women are also asked to indicate drug tolerability using a NRS and to rate the degree of satisfaction with their treatment.

The above scales and questionnaires have been described previously in detail [7, 13-16]. The presence and severity of dysmenorrhea, deep dyspareunia, non-menstrual pelvic pain, and dyschezia were assessed using an 11-point NRS, with 0 indicating absence of pain and 10 pain as bad as it could be. Patients were also asked to grade the severity of the above symptoms using a 0- to 3-point

MCRS modified from that devised by Biberoglu and Behrman [33]. Irregular bleeding during treatment was defined as spotting (scanty bleeding requiring ≤ 1 pad or tampon per day) or breakthrough bleeding (light or moderate bleeding requiring ≥ 2 pads or tampons per day). Pain during spotting or breakthrough bleeding was considered as dysmenorrhea.

The SF-12 health survey, developed from the original SF-36 questionnaire [34, 35], is a well know, validated self-administered 12-item instrument. It measures health dimensions covering functional status, well-being, and overall health. Information from the 12 items is used to construct physical (PCS-12) and mental (MCS-12) component summary measures [36, 37], with higher scores indicating better health perception.

The HADS questionnaire is a self-assessment mood scale specifically designed for use in non-psychiatric hospital outpatients to determine states of anxiety and depression. It comprises 14 questions, 7 for the anxiety subscale and 7 for the depression subscale. Lower scores indicate better psychological status [38].

The FSFI questionnaire is a 19-item, multidimensional, self-report instrument for evaluating the main categories of female sexual dysfunction and sexual satisfaction [39-41]. The transformed maximum score for each domain is 6, and the maximum (best) transformed full-scale score is 36, with a minimum full-scale score of 2.0.

Occurrence of side effects associated with medical treatments is actively investigated in our endometriosis outpatient clinic, and the overall tolerability of hormonal therapies is measured using a 0- to10-point NRS, with 0 indicating absolutely intolerable untoward effects and 10 absence of adverse effects. Scores are then categorized, with 9-10 indicating that a drug is very well tolerated; 7-8, well tolerated; 5-6, moderately tolerated; 3-4, poorly tolerated; 0-2, not tolerated [16].

Patients rated the degree of satisfaction after the modification of their treatment according to a five-category scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied) by answering the following question: “Taking into consideration the variations occurred in side effects and overall tolerability of treatment, pain symptoms, physical and

psychological well-being, health-related quality of life, and sexual functioning, how would you define the level of satisfaction with your current treatment?" In order to limit the potential effect of confounding, satisfaction with treatment, the main study outcome, was dichotomized into "satisfied" (very satisfied plus satisfied) and "dissatisfied" (neither satisfied nor dissatisfied plus dissatisfied plus very dissatisfied).

Data management

The focus of the investigation was not a head-to-head comparison between OC and NETA but, instead, quantification of the proportion of women who were satisfied with a change in treatment 12 months after OC or NETA discontinuation because of intolerance. No study is available to define the potential benefits of shifting from OC to NETA or viceversa in this clinical condition. Therefore, a pre-planned power calculation was not performed, and we decided to include all the eligible patients evaluated in a 12-month period.

Data were archived using Excel 2003 (Microsoft Corporation, Redmond, Washington, U.S.A.) and exported in SPSS 18.0 (SPSS, Inc, Chicago, IL, U.S.A.) or SAS software 9.4 (SF-12 data; SAS Institute Inc., Cary, NC, U.S.A.) for statistical analysis. Estimate of patient satisfaction rate was performed according to the intention-to-treat principle, considering as dissatisfied all patients who dropped out of the study for any reason except conception seeking, thus including request for surgery and lost to follow-up. Variations in drug tolerability, pelvic pain symptoms, health-related quality of life, psychological status, and sexual functioning between baseline and 12-month values were evaluated by using the paired Student *t* test for normally distributed data, the non-parametric Wilcoxon matched pairs test for non-normally distributed data, the McNemar test for categorical variables, and the Fisher Exact test in case of cells without numerical data. Determinants of satisfaction with treatment were investigated with unpaired tests (Student *t* test for normally distributed continuous variables, Wilcoxon test for non-normally distributed continuous variables, and the chi-squared test for categorical variables). All statistical tests were two-sided. A *P*

value < 5% was considered statistically significant. When appropriate, 95% confidence intervals (CIs) were calculated for the observed differences by applying a binomial distribution model.

RESULTS

A total of 35 women shifted from OC to NETA, and 32 from NETA to OC. The distribution of demographic and clinical characteristics of the patients in the two study groups are shown in Table 1.

a. Switch from OC to NETA

The median duration [interquartile range, IQR] of OC use was 6 months [3-14]. Nineteen women (54%) were using OC cyclically and 16 (46%) continuously. The most frequent untoward effects that determined the request for OC discontinuation despite an appreciable effect on pain symptoms were headache (49%), breakthrough bleeding (14%), and weight gain (11%). Eight women (23%) dropped out from the study between the 6- and 12-month evaluation owing to persistence of (headache, $n = 3$) or onset of different (mood changes, $n = 1$; urticarial rash, $n = 1$; breakthrough bleeding, $n = 1$) side effects, onset of non-menstrual pelvic pain ($n = 1$), and unwillingness to undertake any further treatment ($n = 1$). Variation of frequency of side effects associated with the shift from OC to NETA in the 27 women who completed the 12-month study period is reported in Table 2. None of the differences were statistically significant. A trend was observed toward a decrease in frequency of headache (from 56% to 30%) and an increase in that of weight gain (from 30% to 44%). However, the severity of untoward effects decreased significantly, as the mean ± SD tolerability NRS score increased from 3.0 ± 1.6 to 5.7 ± 2.4 ($P < 0.001$). Ten women (37%) reported good or very good (NRS ≥ 7) drug tolerability, compared with none at baseline.

The severity of pain symptoms did not vary significantly except for dysmenorrhea that decreased at evaluation by means of the NRS (Table 3). Overall, the frequency of moderate or severe complaints was marginal at both baseline and 12-month assessment. No substantial variations were observed also in psychological status and sexual functioning. With regard to health-related quality of life, a significant improvement was reported only in the physical component of the

SF-12 questionnaire (Table 3). At the end of the study period 18/35 (51%; 95% C.I., 36% to 67%) women were satisfied or very satisfied with the treatment change, whereas 17/35 (49%; 95% C.I., 33% to 64%) were neither satisfied nor dissatisfied, dissatisfied, or very dissatisfied. All the patients who dropped out from the study were included as dissatisfied in this intention-to-treat analysis.

b. Switch from NETA to OC

The median duration [interquartile range, IQR] of NETA use was 12 months [5-22]. The most frequent untoward effects that determined the request for NETA discontinuation despite an appreciable effect on pain symptoms were weight gain (19%), headache (16%), breakthrough bleeding (16%), decreased libido (16%), spotting (12%), and mood changes (12%). Seven women (22%) dropped out from the study between the 6- and 12-month evaluation owing to persistence of (acne, $n = 1$) or onset of different (headache, $n = 4$) side effects, onset of non-menstrual pelvic pain ($n = 1$), and pregnancy desire ($n = 1$). Variation of frequency of side effects associated with the shift from NETA to OC in the 25 women who completed the 12-month study period is reported in Table 4. Again, none of the differences were statistically significant. A trend was observed toward a decrease in frequency of weight gain (from 36% to 16%), decreased libido (from 44% to 32%), and vaginal dryness (from 36% to 24%), and an increase in that of headache (from 20% to 40%). However, the severity of untoward effects decreased significantly, as the mean ± SD tolerability NRS score increased from 3.5 ± 1.7 to 6.9 ± 2.5 ($P < 0.001$). Thirteen women (52%) reported good or very good (NRS ≥ 7) drug tolerability, compared with none at baseline.

Based on NRS assessment, the severity of deep dyspareunia and non-menstrual pelvic pain decreased significantly (Table 5). A trend was observed toward a decrease in the frequency of moderate to severe deep dyspareunia (eight women at baseline vs three at 12 months) and dyschezia (four and two women, respectively) at MCRS evaluation (Table 5). Significant improvements were observed in both the anxiety and depression HADS subscales scores, as well as in the FSFI scores. No significant variations were reported in both the physical and the mental components of the SF-12 questionnaire (Table 5). One woman who dropped out of the study because of pregnancy desire

was not considered in the intention-to-treat analysis of satisfaction with treatment. At the end of the study period 20/31 (65%; 95% C.I., 47% to 79%) patients were satisfied or very satisfied with the treatment change, whereas 11/31 (35%; 95% C.I., 20% to 52%) were neither satisfied nor dissatisfied, dissatisfied, or very dissatisfied.

DISCUSSION

Overall, the main finding of the present study was that, when OC or NETA are not tolerated, shifting to the other compound allows the majority of patients with endometriosis to improve tolerability and to continue medical treatment with a safe, effective, and unexpensive drug. The benefit seems larger when the shift is from NETA to OC rather than the other way round, as the proportion of satisfied patients at the end of the study period was, respectively, 65% and 51%. Moreover, in the latter case the 95% C.I.s of the rates of satisfied and dissatisfied women amply overlapped, whereas in the former case the 95% C.I. overlapping was marginal.

Considering a shift from OC to NETA may be beneficial especially in women experiencing headache, as previously suggested by Morotti *et al*. [17]. The frequency of the other untoward effects associated with OC use were not reduced, but their severity was, as demonstrated by the increase in 12-month follow-up NRS tolerability score compared with baseline values.

Considering a shift from NETA to OC may be beneficial especially in women experiencing side effects typically associated with this type of progestin, such as weight gain, acne, bloating, and decreased libido. On the other hand, this change may lead to an increase in the frequency of headache, likely associated with the estrogen component. This confirms that OCs with the lowest possible estrogen dose should be chosen also in women with endometriosis in order to improve both safety and tolerability [42-45].

The larger effect observed when the shift was from NETA to OC confirms that low-dose, monophasic estrogen-progestin combinations should retain their role in the management of endometriosis, provided pain symptoms are adequately relieved. In this regard, it should be highlighted that at baseline pain was generally well controlled in both study groups, and that the

focus here was on tolerability, not efficacy on symptoms. This also explains the limited significant variations in pain symptoms' severity independently of the direction of the change between the two medications, demonstrating that the observed amelioration of tolerability was not at detriment of efficacy on pain. Conversely, marginal improvements in the severity of dysmenorrhea when shifting from OC to NETA, and of deep dyspareunia and non-menstrual pain when shifting from NETA to OC were reported, although of questionable clinical importance.

Our study has limitations. The combination of the observational design with the limited sample size increases the risk of confounding. Moreover, the population was highly selected, and this precludes generalization of the results to endometriosis patients with different complaint types. However, the self-controlled design was chosen purposely because the objective of the study was to assess variations in tolerability when shifting to NETA or OC not in a general population using the other drug, but specifically in those patients who were dissatisfied because of intolerable side effects and that would have otherwise discontinued medical therapy. In a self-control study, recruited patients act as their own control, thus limiting the effect of confounding. In fact, study outcomes may be influenced by relevant characteristics that may differ between patients [19]. In addition, overoptimistic results should have been avoided, as patient satisfaction was assessed including all dropouts as dissatisfied.

The period of use of OC and NETA before changing medication was fairly long. Thus, the phenomenon of regression toward the mean seems unlikely, given that the clinical condition was chronic and that all study variables were measured repeatedly before enrollment. Also a carry-over effect should be ruled out, as the baseline patients' conditions were the worst possible in terms of tolerability. Therefore, if a carry-over effect was in play, this was detrimental, not beneficial, again potentially leading to conservative estimates. Also a placebo effect cannot be excluded. However, given the long study period, this seems little probable, as the placebo effect may not last for one year when drug tolerability is unacceptable.

The proportion of dropouts was high and above the usually indicated 20% cut-off over which the study findings are considered of questionable validity [46]. However, this cut-off may not be appropriate when all patients at recruitment are considering abandonment of medical treatment owing to dissatisfaction. In these conditions, a 22-23% dropout rate may even appear fairly low.

Owing to the limited number of participants, the analysis of determinants of success was deemed unreasonable. More in general, the small sample size could have led to some type II errors, thus impeding the identification of potential factors predictive of satisfaction with treatment change. On the other hand, in our experience it is not easy for endometriosis patients to decide to discontinue a medical therapy that is effective on pain, solely because of side effects. In this regard, it may not be excluded that women referred or self-referred to our center are more motivated to choose medical rather that surgical treatment. If this was true, such selection bias would render generalization of the study results more problematic.

However, when discussing generalization, we also believe that our findings provide a realistic picture of what happens in everyday practice, and our data may help clinicians when counselling patients experiencing upsetting untoward effects with OC or NETA. Observational studies may be very helpful in assessing the real world effectiveness of treatments that have already been demonstrated to work in highly controlled research settings [47], as OCs and NETA in women with symptomatic endometriosis [5, 7, 8, 12].

It could also be argued that, in women who were intolerant to NETA, instead of suggesting OC we could have suggested shifting to dienogest, that has been proven to be better tolerated than NETA [16]. However, many women assisted in our center cannot afford the cost of dienogest (€730 - $860 - £ 670 per year in Italy, not reimbursed by the Italian NHS) and prefer NETA (€18 - $21 - £17 per year in Italy, €4 per year when reimbursed by the Italian NHS) specifically for economic reasons. Indeed, we previously demonstrated that the cost of dienogest limited its effectiveness despite its good tolerability [16]. Moreover, here the issue was not poor pain control, but drug

intolerance, and indeed the larger benefit was observed precisely when shifting from NETA to OC. Thus, changing for dienogest would have led to waste of money in the majority of patients.

In conclusion, when endometriosis-associated pain was relieved by OC or NETA, but the medications could no longer be used because of intolerable side effects, shifting to the other compound resulted in substantial improvement of tolerability in the majority of women. The change of therapy was particularly beneficial in patients using NETA who shifted to OC. Women should be informed about this further therapeutic option in order to be enabled to choose a treatment modification that is aligned with their preferences and priorities.

DISCLOSURE STATEMENT (CONFLICT OF INTEREST)

PV, FO, MPF, LB, and AR declare that they have no conflicts of interest. ES received grants from Ferring and Serono.

REFERENCES

1. ACOG Practice Bulletin No. 114: Management of endometriosis. Obstet Gynecol 2005;116:223-36.

2. Leyland N, Casper R, Laberge P, Singh SS; SOGC: Endometriosis: diagnosis and management. J Obstet Gynecol Can 2010;32:S1-32.

3. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology: ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29:400-12.

4. Practice Committee of the American Society for Reproductive Medicine: Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014;101:927-35.

5. Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG: A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75-9.

6. Muneyyirci-Delale O, Karacan M: Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med 1998;43:24–7.

7. Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG: Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005;84:1375-87.

8. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N: Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008;90:1583-8.

9. Ferrero S, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V: Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod 2009;24:3033–41.

10. Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Remorgida V: Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. Hum Reprod 2010;25:94–100.

11. Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Seracchioli R, Remorgida V: Letrozole and norethisterone acetate in colorectal endometriosis. Eur J Obstet Gynecol Reprod Biol 2010;150:199-202.

12. Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S: Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril 2010;94:464-71.

13. Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L: Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010;93:2150-2161.

14. Vercellini P, Somigliana E, Consonni D, Frattaruolo MP, De Giorgi O, Fedele L: Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum Reprod 2012;27:3450-9.

15. Vercellini P, Frattaruolo MP, Somigliana E, Jones GL, Consonni D, Alberico D, Fedele L: Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod 2013;28:1221-30.

16. Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, Somigliana E: Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 2016;105:734-743.

17. Morotti M, Remorgida V, Venturini PL, Ferrero S: Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol 2014;179:63-8.

18. Berlanda N, Somigliana E, Viganò P, Vercellini P: Safety of medical treatments for endometriosis. Expert Opin Drug Saf 2016;15:21-30.

19. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L: Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ 2013;346:f1936.

20. Eskenazi B, Warner M, Bonsignore L, Olive D, Samuels S, Vercellini P: Validation study of nonsurgical diagnosis of endometriosis. Fertil Steril 2001;76:929-35.

21. Vercellini P, Somigliana E, Cortinovis I, Bracco B, de Braud L, Dridi D, Milani S: "You can't always get what you want": from doctrine to practicability of study designs for clinical investigation in endometriosis. BMC Womens Health 2015;15:89.

22. Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S: Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril 2016;106:1552-1571.

23. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG: Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003;9:387-96.

24. Vercellini P, Crosignani P, Somigliana E, Viganò P, Frattaruolo MP, Fedele L: 'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis. Hum Reprod 2011;26:3-13.
25. Vercellini P, Giudice LC, Evers JL, Abrao MS: Reducing low-value care in endometriosis between limited evidence and unresolved issues: a proposal. Hum Reprod. 2015;30:1996-2004.
26. Bedaiwy MA, Allaire C, Yong P, Alfaraj S: Medical Management of Endometriosis in Patients with Chronic Pelvic Pain. Semin Reprod Med 2017;35:38-53.
27. Vercellini P, Facchin F, Buggio L, Barbara G, Berlanda N, Frattaruolo MP, Somigliana E: Management of endometriosis: toward value-based, cost-effective, affordable care. J Obstet Gynaecol Can 2017 (in press).
28. Guo SW: Recurrence of endometriosis and its control: Hum Reprod Update 2009;15:441-61.
29. Vercellini P, Crosignani PG, Abbiati A, Somigliana E, Viganò P, Fedele L: The effect of surgery for symptomatic endometriosis: the other side of the story. Hum Reprod Update 2009;15:177-88.
30. Kaser DJ, Missmer SA, Berry KF, Laufer MR: Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol 2012;25:105–8.
31. Muneyyirci-Delale O, Anopa J, Charles C, Mathur D, Parris R, Cutler JB, Salame G, Abulafia O: Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health 2012;4:149–54.
32. Ferrero S, Remorgida V, Venturini PL, Leone Roberti Maggiore U: Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstet Gynecol Reprod Biol 2014;174:117–22.

33. Biberoglu KO, Behrman SJ: Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol 1981;139:645–54.
34. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
35. McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247–63.
36. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–33.
37. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M: Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51:1171–8.
38. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–70.
39. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr: The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
40. Meston CM: Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003;29:39–46.
41. Wiegel M, Meston C, Rosen R: The female Sexual Function Index (FSFI): cross-validation and development of clinical cut-off scores. J Sex Marital Ther 2005;31:1–20.
42. De Leo V, Musacchio MC, Cappelli V, Piomboni P, Morgante G: Hormonal contraceptives: pharmacology tailored to women's health. Hum Reprod Update 2016;22:634-46.
43. Sitruk-Ware R: Hormonal contraception and thrombosis. Fertil Steril 2016;106:1289-1294.

435 44. Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière PO, Rudant J, Alla F, Zureik
436 M: Low dose oestrogen combined oral contraception and risk of pulmonary embolism,
437 stroke, and myocardial infarction in five million French women: cohort study. BMJ
438 2016;353:i2002.
439 45. Calhoun AH: Hormonal Contraceptives and Migraine With Aura-Is There Still a Risk?
440 Headache. 2017;57:184-193.
441 46. Unnebrink K, Windeler J: Intention-to-treat: methods for dealing with missing values
442 in clinical trials of progressively deteriorating diseases. Stat Med 2001;20:3931-46.
443 47. Marley J: Efficacy, effectiveness, efficiency. Aust Prescr 2000;23:114-5.
444

445

Table 1. Distribution of baseline demographic and clinical characteristics of women who shifted to norethisterone acetate (NETA) for intolerance to low-dose oral contraceptive (OC), and of women who shifted to OC for intolerance to NETA.

Characteristic	From OC to NETA study group (n = 35)	From NETA to OC study group (n = 32)
Age (years)	35.5 ± 4.7	34.2 ± 5.3
BMI (Kg/m^2)	23.6 ± 4.0	20.5 ± 2.6
Smoking	6 (17%)	9 (28%)
Previous deliveries	15 (43%)	6 (19%)
Previous surgical procedures for endometriosis		
None	9 (26%)	14 (44%)
1	18 (51%)	11 (34%)
2	7 (20%)	5 (16%)
≥ 3	1 (3%)	2 (6%)
Endometriotic lesion type[a]		
Deep infiltrating endometriosis	17 (49%)	24 (75%)
Ovarian endometriomas	28 (80%)	18 (56%)
Pain symptoms[b]		
Dysmenorrhea	15 (42%)	8 (25%)
Deep dyspareunia	5 (15%)[c]	15 (30%)[d]
Non-menstrual pelvic pain	5 (14%)	12 (37%)
Dyschezia	2 (6%)	7 (22%)
Duration of previous treatment [months]	6 [3-14]	12 [5-22]

Data is reported as mean ± SD, or number (percentage), or median [interquartile range].
NETA = norethisterone acetate. OC = low-dose, combined oral contraceptive. BMI = body mass index.
[a] The sum does not add to the total as some women had both lesion types.
446 [b]Numeric rating scale > 0. Mild pain symptoms are also included.
447 [c]One woman did not have sexual intercourses at basal and/or at 12-month evaluation.
448 [d]Two women did not have sexual intercourses at basal and/or at 12-month evaluation

449

450

Table 2. Per-protocol analysis of frequency of side effects reported at baseline and at 12-month evaluation by patients (n = 27) shifting from OC to NETA.

Side effect[a]	Baseline evaluation	12-month evaluation	*P*
Headache	15 (56%)	8 (30%)	NS
Spotting	5 (18%)	6 (22%)	NS
Breakthrough bleeding	1 (4%)	0 (0%)	NS
Weight gain	8 (30%)	12 (44%)	NS
Nausea	2 (7%)	1 (4%)	NS
Decreased libido	7 (26%)	5 (18%)	NS
Vaginal Dryness	4 (15%)	6 (22%)	NS
Bloating or swelling	5 (18%)	6 (22%)	NS
Breast tenderness	0 (0%)	4 (15%)	NS
Acne	0 (0%)	3 (11%)	NS
Alopecia	0 (0%)	0 (0%)	NS
Mood changes	5 (18%)	5 (18%)	NS
Others	11 (41%)	9 (33%)	NS

[a]Some women reported more than one side effect.
Data are number (percentage).

451

452

453

454

Table 3. Per-protocol analysis[a] of pain symptoms, health-related quality of life, psychological status, and sexual functioning scores variation between baseline and 12-month evaluation in patients (n = 27) shifting from OC to NETA.

Symptoms / Questionnaires	Baseline evaluation	12-month evaluation	*P*
Dysmenorrhea			
NRS	0 [0-4]	0 [0-0]	0.01
MCRS ≥ 2	2 (7%)	0 (0%)	NS
Deep dyspareunia[b]			
NRS	0 [0-0]	0 [0-0]	NS
MCRS ≥ 2	1 (4%)	2 (8%)	NS
Non-menstrual pelvic pain			
NRS	0 [0-0]	0 [0-0]	NS
MCRS ≥ 2	1 (4%)	0 (0%)	NS
Dyschezia			
NRS	0 [0-0]	0 [0-0]	NS
MCRS ≥ 2	1 (4%)	0 (0%)	NS
SF-12			
Physical component	50.0 ± 11.1	55.4 ± 4.5	0.03
Mental component	40.0 ± 11.7	42.6 ±13.2	NS
HADS			
Anxiety	6.6 ± 4.3	5.9 ± 4.6	NS
Depression	5.8 ± 4.3	5.4 ± 5.1	NS
Total	12.4 ± 8.1	11.3 ± 9.1	NS
FSFI total score[b]	26.2 ± 5.7	26.2 ± 6.7	NS

Data is reported as mean ± SD, or number (percentage), or median [interquartile range].
NRS = 0 to 10-point numeric rating scale. MCRS = 0 to 3-point multidimensional categorical rating scale modified from that devised by Biberoglu and Behrman [33].
SF-12 = Short Form-12 [36, 37]. HADS = Hospital Anxiety and Depression Scale [38].
FSFI = Female Sexual Function Index [39, 40].
NS = not significant.
[a]Women who withdrew before 12-month follow-up assessment (n = 8) were excluded.
[b]One woman did not have sexual intercourses either at baseline and/or at 12-month evaluation.

455

Table 4. Per-protocol analysis of frequency of side effects reported at baseline and at 12-month evaluation by patients (n = 25) shifting from NETA to OC.

Side effect[a]	Baseline evaluation	12-month evaluation	*P*
Headache	5 (20%)	10 (40%)	NS
Spotting	4 (16%)	7 (28%)	NS
Breakthrough bleeding	3 (12%)	0 (0%)	NS
Weight gain	9 (36%)	4 (16%)	NS
Nausea	2 (8%)	0 (0%)	NS
Decreased libido	11 (44%)	8 (32%)	NS
Vaginal Dryness	9 (36%)	6 (24%)	NS
Bloating or swelling	4 (16%)	2 (8%)	NS
Breast tenderness	0 (0%)	0 (0%)	NS
Acne	2 (8%)	0 (0%)	NS
Alopecia	0 (0%)	0 (0%)	NS
Mood changes	5 (20%)	1 (4%)	NS
Others	5 (20%)	1 (4%)	NS

[a]Some women reported more than one side effect.
Data are number (percentage).

456

457

458

459

460

461

462

463

464

Table 5. Per-protocol analysis[a] of pain symptoms, health-related quality of life, psychological status, and sexual functioning scores variation between baseline and 12-month evaluation in patients (n = 25) shifting from NETA to OC.

Symptoms / Questionnaires	Baseline evaluation	12-month evaluation	*P*
Dysmenorrhea			
NRS	0 [0-1.5]	0 [0-3]	NS
MCRS ≥ 2	0 (0%)	1 (4%)	NS
Deep dyspareunia[b]			
NRS	5 [0-8]	0 [0-5.5]	0.02
MCRS ≥ 2	8 (35%)	3 (13%)	NS
Non-menstrual pelvic pain			
NRS	0 [0-4.5]	0 [0-0]	0.02
MCRS ≥ 2	2 (8%)	1 (4%)	NS
Dyschezia			
NRS	0 [0-1.5]	0 [0-0]	NS
MCRS ≥ 2	4 (16%)	2 (8%)	NS
HADS			
Anxiety	4.7 ± 3.5	3.6 ± 3.2	0.02
Depression	5.4 ± 4.0	3.8 ± 3.4	0.03
Total	10.1 ± 7.3	7.4 ± 6.3	0.02
SF-12			
Physical component	52.8 ± 9.1	54.8 ± 4.4	NS
Mental component	42.1 ± 11.7	46.1 ± 10.0	NS
FSFI total score[b]	21.9 ± 8.6	25.4 ± 7.9	0.01

Data is reported as mean ± SD, or number (percentage), or median [interquartile range].
NRS = 0 to 10-point numeric rating scale. MCRS = 0 to 3-point multidimensional categorical rating scale modified from that devised by Biberoglu and Behrman [33].
SF-12 = Short Form-12 [36, 37]. HADS = Hospital Anxiety and Depression Scale [38].
FSFI = Female Sexual Function Index [39, 40].
NS = not significant.
[a]Women who withdrew before 12-month follow-up assessment (n = 7) were excluded.
[b]One woman did not have sexual intercourses either at baseline and/or at 12-month evaluation.